Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Invest New Drugs. 2015 Dec 14;34(2):168–175. doi: 10.1007/s10637-015-0314-7

Table 2.

Dose escalation schema and frequency of dose limiting toxicities

Dose level Total n of patients Selumetinib, oral dose Cetuximab, IV load/week N of courses N of unevaluable patientsa N of patients with DLTs DLT description
1 7 50mg Daily 400mg/250mg 16 1 1 Hypomagnesemia
2 4 50mg BID 400mg/250mg 12 1 0
3b 22 75mg BID 400mg/250mg 34 7 1c Acneiform rash
a

Patients were unevaluable due to not receiving at least 75% scheduled of selumetinib and cetuximab during cycle 1.

b

Includes patients at dose level 3 and the dose expansion cohort

c

This DLT was observed in the KRAS mutant CRC dose expansion cohort.